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Research
Persistent organic pollutants (POPs), such as 
organochlorine pesticides (OCs) and poly-
chlorinated biphenyls (PCBs), contaminate 
many environmental matrices and can be 
found in human blood, adipose tissue, and 
breast milk (Guvenius et al. 2003; Solomon 
and Weiss 2002). In addition, these POPs 
cross the placenta and have been reported to 
reduce gestational length and birth weight 
and to affect fetal development (Ando et al. 
1985; Guvenius et al. 2003; Lanting et al. 
1998; Rogan et al. 1986; Shen et al. 2007; 
Taylor et al. 1984). Furthermore, some of 
these chemicals may induce endocrine effects, 
and others are classified as “reasonably antici-
pated to be” or “known” human carcino-
gens (Carpenter 2006). Multiple studies have 
shown that the levels of several POPs found 
in the environment, human fat, maternal and 
cord bloods, and breast milk have decreased 
after being banned (Bates et al. 2002; Craan 
and Haines 1998; Norén and Meironyte 
2000; Pereg et al. 2003; Schade and Heinzow 
1998; Solomon and Weiss 2002). However, 
this is not universal; for example, concentra-
tions of PCBs in Great Lakes fish have con-
tinued to oscillate (Bhavsar et al. 2007).
A more recently recognized class of envi-
ronmental contaminant, whose chemical 
structure is similar to PCBs, is the brominated 
flame retardants, which includes the poly-
brominated diphenyl ether (PBDE) congeners 
(Gill et al. 2004; Hites 2004). For the past 
two to three decades, they have been added 
to plastics, polyurethane foam, textiles, and 
electronic equipment to prevent ignition or to 
slow the burn rate if a fire occurs. In animal 
studies, PBDEs have been found to affect neu-
ral and reproductive development as well as 
thyroid function (Birnbaum and Staskal 2004; 
Gill et al. 2004; Legler 2008; McDonald 
2002; Talsness 2008). Although many of these 
investigations used pharmacologic doses of 
the PBDEs, more recent studies have demon- 
strated that exposure at doses relevant for 
humans at critical times during development 
can have effects on the endocrine and neural 
systems (reviewed in Legler 2008; Talsness 
2008). Only two clinical epidemiologic studies 
have been published to date on the potential 
effects of in utero exposure and fetal outcome. 
Chao et al. (2007) recently reported that ele-
vated levels of PBDEs in breast milk correlated 
significantly with lower newborn birth weight, 
birth length, chest circumference, and body 
mass index. In addition, Main et al. (2007) 
have found significantly higher PBDE levels 
in the breast milk of mothers whose newborn 
sons had cryptorchidism. One study of young 
adult males has reported a significant negative 
association between serum brominated diphe-
nyl ether congener BDE-153 levels and testis 
size as well as sperm concentration (Akutsu 
et al. 2008).
In contrast to OCs and PCBs, many stud-
ies worldwide have reported that the amount 
of PBDEs found in the environment, human 
serum, and breast milk has been increasing 
steadily since the 1980s (Akutsu et al. 2003; 
de Wit et al. 2006; Li et al. 2006; Lorber 
2008; Norén and Meironyte 2000; Pereg et al. 
2003; Ryan et al. 2002; Schecter et al. 2004; 
Solomon and Weiss 2002). A few investigators 
in Europe have found that the PBDE levels in 
European samples peaked in 1997–1998 and 
subsequently have plateaued or declined, likely 
due to the earlier limitations on the produc-
tion and use of penta- and octa-BDEs within 
the European Union versus North America 
(Darnerud et al. 2002; Law et al. 2006, 2008).
Human breast milk is only one source of 
environmental contaminants for a developing 
infant, and from a toxicology and regulatory 
perspective, it is the infant’s total body bur-
den that is of greatest interest. Very little is 
known about when in utero exposure begins 
to contribute significantly to an infant’s body 
burden of PBDEs and other POPs. To exam-
ine this question, we analyzed the levels of 
multiple OCs p,p´-DDT (1,1,1-trichloro-
2-[o-chlorophenyl]-2-2[p-chlorophenyl]
ethane), p,p´-DDE (1,1-dichloro-2,2-bis[p-
chloro  phenyl] ethylene), trans-nonachlor, and 
hexachlorobenzene (HCB)], PCB congeners 
(49, 99, 118, 137, 138, 153, and 180), and 
BDE congeners (47, 85, 99, 100, 153, 154, 
and 183) in early to mid-gestation fetal liver 
and placental specimens obtained between 
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Ba c k g r o u n d: There is general concern that persistent organic pollutants (POPs) found in the 
environment, wildlife, food, water, house dust, human tissues, and fluids may alter normal human 
physiologic activities (e.g., fetal development, immune and endocrine systems). Although the levels 
of some POPs [polychlorinated biphenyls (PCBs) and organochlorine pesticides (OCs)] in these 
matrices have decreased after their ban, others [polybrominated diphenyl ethers (PBDEs)] have 
increased in recent years.
oB j e c t i v e: To determine the longitudinal trend of specific POPs in human fetal tissues for risk 
assessment purposes.
Me t h o d s : We analyzed early to mid-gestation fetal liver (n = 52) and placental (n = 60) tissues, 
obtained after elective abortions during 1998–2006, for selected PBDEs, PCBs, and OCs using gas 
chromatography–mass spectroscopy.
re s u l t s: Total PBDEs in fetal liver increased over time (mean ± SE: 1998, 284.4 ± 229.8 ng/g 
lipid; 2006, 1,607.7 ± 605.9; p < 0.03), whereas placental levels were generally lower, with no clear 
trend. Low levels of PCBs and OCs varied yearly, with no evident trend. The major analytes in 
1998 were OCs (liver, 49%; placenta, 71%), whereas the major analytes in 2006 were PBDEs (liver, 
89%; placenta, 98%). The 1998–2006 tissue PBDE congener profile is similar to that of DE-71, a 
commercial primarily pentabrominated diphenyl ether mixture manufactured in North America.
co n c l u s i o n s: Although commercial production of penta- and octa-brominated diphenyl ethers in 
North America was halted in 2004, their concentrations in fetal liver and placenta are now greater 
than the tissue burdens for the analyzed OCs and PCBs. Our findings also demonstrate that PBDEs 
accumulate within the fetal compartment at a very early stage in gestation.
key w o r d s : fetus, human, liver, placenta, OCs, PBDEs, PCBs, POPs. Environ Health Perspect 
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1998 and 2006. The results are an expanded 
version of data presented previously at two sci-
entific meetings (Doucet et al. 2004, 2007).
Materials and Methods
Sample collection and storage. We obtained 
human fetal liver and placental (villous region) 
samples (fetal age, 9.5–20 weeks) after elective 
pregnancy terminations during 1998–2006 
in the Greater Montreal area of Quebec with 
informed written consent. Fetal ages were 
determined by foot length (Munsick 1984). 
The tissues were placed in sterile vials and 
flash-frozen in a dry ice/acetone bath, initially 
stored at McGill University (–80°C), and 
then transferred in dry ice to Health Canada 
for processing. We collected a total of 52 liver 
and 60 placental samples, with 36 paired sam-
ples from the same fetuses. No information 
was available concerning the mothers because 
the tissues were collected anonymously. Ethics 
approval for the collection and use of the 
human fetal tissues was obtained from McGill 
University and Health Canada.
Analyte/lipid extraction. We precleaned 
all glassware, except volumetric flasks and 
custom-made columns, in a dishwasher and 
baked them at 475°C for 2 hr in a Tempyrox 
oven (Tempyrox Co., Dallas, TX, USA). The 
volumetrics and custom-made columns were 
cleaned by solvent rinsing with acetone fol-
lowed by hexane. We thawed approximately 
1 g of each sample at room temperature in 
50-mL centrifuge tubes and homogenized 
them in 20 mL of a 2:1 acetone/hexane solu-
tion for 1 min using a Polytron homogenizer 
(Brinkmann, Mississauga, ON, Canada). 
The resulting supernatant was quantitatively 
transferred and filtered through precleaned 
(dichloromethane) glass wool, collected in 
250-mL round-bottom flasks (RBFs), and 
concentrated to approximately 1 mL on a 
rotary evaporator (Buchii, New Castle, DE, 
USA). The extracts were dried by pour-
ing them into funnels containing prebaked 
sodium sulfate (700°C, overnight) and again 
collected in 250-mL RBFs. We then trans-
ferred the dried extracts to preweighed 10-mL 
vials for gravimetric lipid determinations.
Sample cleanup. We performed sample 
cleanup on a 12-mm outer-diameter × 22-cm 
glass column containing 2% water-deactivated 
Florisil. Extracts were eluted using 70 mL 
hexane. This fraction contained BDE conge-
ners (28, 47, 85, 99, 100, 153, 154, and 183), 
PCB congeners (49, 99, 118, 137, 138, 153, 
and 180), and several OCs (p,p´-DDT, p,p´-
DDE, trans-nonachlor, HCB). We selected 
these analytes based on previous studies of 
Canadian breast milk samples showing that 
they had the highest levels and occurrences in 
1992 and 2002 (Newsome et al. 1995; Ryan 
et al. 2002). In addition, the PBDE congeners 
matched those in the commercial mixture 
DE-71 (Chemtura Corp., Middlebury, CT, 
USA), which contains primarily penta-BDEs 
(Table 1). The Florisil extracts were trans-
ferred to 2-mL tapered chromatography tubes 
(Kontes, Vineland, NJ, USA) for concentra-
tion under vacuum. Liver extracts were con-
centrated to 300 µL and the placental extracts 
to 100 µL for gas chromatograph–mass spec-
trometer (GC-MS) injection.
Sample analysis. We analyzed samples 
using an Agilent 6890N/5973 GC-MS system 
operated in electron impact ionization mode 
equipped with an Agilent 7683 autosampler 
(Agilent Technologies, Mississauga, ON, 
Canada). Aliquots of 2 µl were injected via 
an on-column injector operated in oven-
track mode. The capillary column employed 
was a 30 m × 0.25 mm × 250 µm DB5-MS 
(Agilent Technologies) coupled to a 2-m × 
0.53-mm deactivated fused silica column 
(Chromatographic Specialties, Brockville, 
ON, Canada). The GC oven parameters were 
80°C for 2 min; 8°C/min to 220°C, 4 min 
hold; 5°C/min to 230°C; 10°C/min to 295°C; 
10 min hold. The helium carrier gas was set at 
a constant flow rate of 1.2 mL/min and the 
transfer line temperature was maintained at 
295°C (MS source, 250°C; MS quad, 150°C). 
Supplemental Material, Table 1 (http://www.
ehponline.org/members/2008/0800205/
suppl.pdf) provides the mass-to-charge ratios 
monitored for the target ions and qualifier 
ions as well as the expected qualifier response 
factors and response factor tolerances.
Calibration and quality control. External 
standard calibration was used after determi-
nation of the instrument’s linear response 
range for each analyte. We based positive 
identification of target compounds on three 
criteria: a chromatographic retention time 
matched to analytical standards, a signal-
to-noise ratio of > 3, and qualifier ion ratios 
within the tolerances listed in Supplemental 
Material, Table 1 (http://www.ehponline.org/
members/2008/0800205/suppl.pdf). Analyte 
concentrations in the samples were calculated 
based on the equation of the linear regres-
sion line after forcing through the origin. The 
response was linear for all analytes (r2 > 0.99).
Instrument sequences consisted of one 
reagent blank, one corn oil sample (no back-
ground POPs) spiked with the analytes, one 
standard reference material (SRM) sample 
(WMF-01 freeze-dried fish tissue; Wellington 
Laboratories, Guelph, ON, Canada), and seven 
tissue samples [see Supplemental Material, 
Figures 1–5 (http://www.ehponline.org/
members/2008/0800205/suppl.pdf)]. The 
BDE background contamination levels fluc-
tuate almost daily, as determined from the 
reagent blanks; therefore, we subtracted this 
value from the spike, the SRM, and the tis-
sue samples on a batch-to-batch basis. Control 
charts were used to monitor the performance 
of the SRM and corrective action was under-
taken any time the warning limit (mean ± 2σ) 
was approached. Recoveries from the spiked 
corn oil sample were also monitored on a 
batch-to-batch basis. Supplemental Material, 
Table 2, provides mean recovery values (http://
www.ehponline.org/members/2008/0800205/
suppl.pdf). Method detection limits (MDLs) 
for each analyte were determined using eight 
corn oil samples (100 mg) spiked with a 
known concentration of each analyte; linear-
ity was established between 7 and 900 ng/mL 
[Supplemental Material, Figure 3 (http://www.
ehponline.org/members/2008/0800205/suppl.
pdf)]. The corn oil spikes were then extracted 
as outlined above and the mean concen-
trations for each analyte calculated. We cal-
culated the MDL as the SD for the replicates 
(n = 8) multiplied by 2.31 (Student’s t-value for 
8 degrees of freedom). Supplemental Material, 
Table 2, lists MDLs (http://www.ehponline.
org/  members/2008/0800205/suppl.pdf).
This extraction methodology has been used 
in our laboratory for many years to evaluate 
POPs in various matrices (Bondy et al. 2003, 
2004). The GC-MS method allows for the 
concurrent analysis and quantification of sev-
eral OC pesticides and PCB and PBDE conge-
ners, facilitating extensive data acquisition from 
small specimens.
Statistical analysis. The data in Figure 1 
are log10 concentrations [nanograms per 
gram lipid weight (lw); mean ± SE] of total 
PBDEs, PCBs, and OCs. Figures 2–4 present 
the data on total and individual PBDE conge-
ners as scatter plots (log10 tissue concentration, 
nanograms per gram lipid); the dashed line 
represents the trend with time (1998–2006) 
using all of the samples per year (i.e., includ-
ing zeros), and the solid line, the trend using 
only samples with detectable levels of PBDEs. 
We analyzed the data using a nonparamet-
ric approach because of the existence of zeros 
(nondetects) and values below the MDL that 
prevented a transformation from achiev-
ing normality. The nonparametric measure 
Table 1. Comparison of the congener composition 
of DE-71 (commercially available PBDE mixture) 
and PBDEs found in human fetal liver and placenta 
from 1998 through 2006.
  Human fetal tissues 
  (average for 1998–2006)
BDE congener  DE-71a (%)  Liver (%)  Placenta (%)
28  0.21  ND  ND
47  42–46  30.4  36.1
85  1.7  1.8  2.1
99  40–41  45.1  42.8
100  7.1–7.7  11.9  11.0
153  2.7–4.4  3.9  4.0
154  2.3–3.1  6.1  3.8
183  ND  0.8  0.3
ND, not determined.
aBased on analyses by the authors of DE-71 supplied by 
the Great Lakes Chemical Corporation. POP residues in human fetal liver and placenta
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of correlation, Kendall’s tau statistic (Daniel 
1978), was used to test for trends. When using 
a nonparametric approach, the use of a zero 
or a value below the MDL does not affect the 
results. The SAS version 9.1 program (SAS 
Institute Inc., Cary, NC, USA) was used to 
create the trend curves in Figures 2–4.
Results
Figure 1 shows the total amounts of PBDEs, 
PCBs, and OCs on a lipid basis in our fetal 
liver and placental samples from 1998 through 
2006. In general, the levels of these POPs 
were severalfold higher in the liver than the 
placenta. The marked “within-year” varia-
tions occurred because some specimens had 
little or no detectable analyte, whereas others 
from the same year contained large amounts 
(Figures 2–4). This was especially noticeable 
with PBDEs in the placenta, where one sam-
ple might have undetectable levels of PBDEs, 
and another, two to three log units (Figures 
2 and 4). However, even with this variabil-
ity, the average relative concentration for each 
of the BDE congeners from 1998 through 
2006 was very similar to the commercial mix-
ture DE-71, which contains primarily penta- 
brominated diphenyl ethers, with congeners 
BDE-99, BDE-47, and BDE-100 as the major 
contributors (Table 1). In addition, we found 
marked changes during the tissue collection 
period regarding the relative amounts of OCs, 
PCBs, and PBDEs in the liver and placenta: 
the major contaminants were OCs in 1998 
but PBDEs in 2006 (Figure 5).
Examination of the “zero” samples showed 
that all tissue samples had detectable PBDE, 
PCB, and/or OC contaminants and that more 
placental samples than liver samples showed 
undetectable PBDEs, PCBs, or OCs (Figure 2). 
We found no significant trends for the number 
of liver or placental samples with undetectable 
PBDEs, PCBs, or OCs (Figures 2–4); only 2 
of the 36 paired liver and placental samples 
showed a parallel lack of PBDEs, and only one 
paired sample showed a parallel lack of PCBs 
(data not shown).
Kendall’s tau test for trend revealed no sig-
nificant changes from 1998 through 2006 in 
any of the individual OC analytes or total OCs 
in either the fetal liver or placental tissues. The 
major OC in both tissues was p,p´-DDE [see 
Supplemental Material, Table 3 (http://www.
ehponline.org/members/2008/0800205/suppl.
pdf)]. Of the PCBs, only PCB 180 showed 
a significant trend: a decrease with time and 
only in liver (r = –0.35, p < 0.003). The major 
PCB congener in both tissues was PCB 153 
[see Supplemental Material, Table 3 (http://
www.ehponline.org/members/2008/0800205/
suppl.pdf)].
In contrast, the total PBDE concentration 
significantly increased in liver during the sam-
pling period (r = 0.22, p < 0.03; Figure 2A), 
Figure 2. Log10 concentrations of total PBDEs (ng/g lw) in human fetal liver (A) and placenta (B) from 1998 
through 2006. The scatter plots illustrate the samples with detectable PBDEs. Numbers below the x-axis 
are the percentages of samples per year that had detectable levels. The dashed line represents the trend 
over the 9-year period using all of the samples per year (i.e., including zeros), and the solid line shows the 
trend using only samples with detectable levels of PBDEs. Statistical analyses of trends were done using 
the data from all samples.
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Figure 1. Yearly levels of total PBDE congeners (47, 85, 99, 100, 153, 154, and 183), total PCB congeners 
(49, 99, 118, 137, 138, 153, and 180), and total OCs (DDT, DDE, trans-nonachlor, HCB) in human fetal liver 
(A; n = 4–8/year) and human fetal placenta (B; n = 4–10/year) obtained from elective terminations of 9.5- to 
20-week fetuses in the Greater Montreal area of Quebec during 1998–2006. The data are mean ± SE (log10 
concentrations, ng/g lw) for all of the samples analyzed.
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Figure 3. Log10 concentrations (ng/g lw) of BDE-47 (A), BDE-100 (B), BDE-154 (C), and BDE-183 (D) in human 
fetal liver during 1998 through 2006. The scatter plots illustrate the samples with detectable congeners. 
Numbers below the x-axis are the percentages of samples per year that had detectable levels. The dashed 
line represents the trend over the 9-year period using all of the samples per year (i.e., including zeros), and 
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as did several of the individual congeners: 
BDE-47 (r = 0.20, p < 0.04; Figure 3A), BDE-
100 (r = 0.24, p < 0.02; Figure 3B), BDE-153 
(r = 0.29, p < 0.006; data not shown but similar 
to BDE-154), BDE-154 (r = 0.29, p < 0.007; 
Figure 3C), and BDE-183 (r = 0.35, p < 0.002; 
Figure 3D). The increase in BDE-99 was not 
quite significant (r = 0.19, p < 0.065; data not 
shown). In the placental specimens, there was 
a significant increase in BDE-85 (r = 0.23, 
p < 0.04; Figure 4A), BDE-153 (r = 0.22, 
p < 0.03; Figure 4B), and BDE-154 (r = 0.31, 
p < 0.002; Figure 4C), but not total PBDEs 
(Figure 2B).
Kendall’s tau test for correlation found no 
correlations for any of the analytes in the 36 
paired human fetal liver and placental samples 
(fetal age, 9.5–19 weeks). Because of the lim-
ited number of samples per year, it was not 
possible to analyze statistically whether there 
was a correlation between the age of the fetus 
and the amount of POPs in the tissue samples; 
however, we found no apparent associations 
when we graphed the data (data not shown).
Discussion
The PBDE levels in human tissue and fluid 
specimens from North America are some of 
the highest in the world (Lorber 2008; Mazdai 
et al. 2003; Ryan et al. 2002; Schecter et al. 
2004). This raises health and regulatory con-
cerns because of the chemical similarities 
between PCBs and PBDEs, and because lev-
els of PBDEs in human samples from North 
America appear to be rising, whereas they are 
generally static or currently decreasing in many 
other parts of the world (Birnbaum and Staskal 
2004; Law et al. 2008; Lorber 2008). Of par-
ticular concern are the reports that young 
infants have higher tissue concentrations than 
do older children and adults, because it is gen-
erally believed that young infants are more vul-
nerable to toxicologic insults (Birnbaum and 
Hubal 2006; Fischer et al. 2006; Thomsen 
et al. 2002; Toms et al. 2008). In utero expo-
sure is also considered to be a critical period 
(Chao et al. 2007; Main et al. 2007); however, 
there is a general scarcity of data regarding 
POP levels in fetal tissues. This hampers regu-
latory assessment of health risks during the 
earliest stages of human development.
Although several studies have analyzed the 
OC and PCB contents of fetal, newborn, and 
infant specimens (Carpenter 2006; Guvenius 
et al. 2003; Solomon and Weiss 2002), only 
a few groups have examined PBDEs, and they 
have focused primarily on the term newborn. 
Four studies in Europe and Asia have found 
that the levels of PBDEs in paired term cord 
and maternal sera are relatively low and quite 
similar (Antignac et al. 2008; Bi et al. 2006; 
Guvenius et al. 2003; Hirai et al. 2004). They 
reported median values for total tri- and tetra-
BDEs ranging from 0.4 to 4.4 ng/g (lipid) in 
cord and maternal sera collected from 2000 
to 2004 in Sweden, France, Japan, and China. 
Mazdai et al. (2003) found approximately 
10-fold higher levels in the U.S. samples col-
lected in 2001, but the levels in the maternal 
and cord sera were again similar, with a median 
of approximately 38 ng/g lipid. Three groups 
have analyzed term placental samples; they 
reported total PBDEs of approximately 1 ng/g 
(lipid) for tissues collected in Finland, Japan, 
and Denmark between 1994 and 2002 (Hirai 
et al. 2004; Main et al. 2007; Strandman et al. 
2000). These studies provide insight into the 
transfer of PBDEs within the human feto- 
placental unit, suggesting that, at the end of 
gestation, there is a relatively free passage of 
PBDEs from the maternal blood across the 
placenta.
Only a North American study has exam-
ined PBDE levels in a nonplacental fetal 
tissue: Schecter et al. (2007) analyzed liver 
samples from 11 fetuses (19–37 week fetal 
age) in 2004 who were stillborn or died after 
premature delivery due to multiple con- 
genital abnormalities. They found total PBDE 
median levels of 15.2 ng/g (lipid), with a 
range from 4.0 to 98.5 ng/g; there was no 
correlation between the hepatic PBDE levels 
and increasing fetal age. These PBDE lev-
els were generally lower than what Schecter 
et al. (2004) had previously measured in non- 
pregnant adult female blood or breast milk 
from 2003 samples, or what Mazdai et al. 
(2003) found in North American maternal 
and cord samples from 2001. However, they 
were higher than serum or placental levels in 
European or Asian samples, suggesting that 
both fetal and maternal PBDE body burdens 
are higher in North America.
The fetal liver study by Schecter et al. 
(2007) was a cross-sectional investigation, 
looking only at samples obtained in 2004, and 
was limited to an analysis of PBDE congeners. 
To the best of our knowledge, the present 
study is the first to analyze fetal tissues for sev-
eral POPs over a period of several years during 
which PBDE congener levels in human speci-
mens have been rising exponentially in North 
America. Consequently, these data should be 
of benefit to agencies concerned with in utero 
exposure and health risks from these environ-
mental contaminants. 
The major findings from our study are as 
follows: 
•	Although there was little change in the con-
centrations of OCs or PCB congeners in 
fetal liver or placenta from 1998 through 
2006, there was a significant increase in liver, 
but not in placenta, of PBDE congeners. 
•	In general, the levels of all of the contami-
nants were severalfold higher in the liver 
than in the placental tissues, and there was 
no correlation for any of the contaminants 
in paired samples. 
•	There was high variability in tissue contami-
nant levels, especially with the placental 
  samples.
Our finding of a significant shift in 
Canadian fetal tissues from primarily OC/PCB 
contaminants to PBDEs in the period from 
1998 through 2006 is not surprising. The wide-
spread banning of several POPs that are envi-
ronmental contaminants (e.g., DDT, PCBs) in 
the 1970s and 1980s has produced a decline in 
their relative concentrations in various matri-
ces, including human specimens, during the 
past 30 years (Norén and Meironyte 2000; 
Pereg et al. 2003). In addition, although a 
limitation on the production and use of penta- 
and octa-BDEs in many countries in Europe 
Figure 4. Log10 concentrations of BDE congeners (ng/g lw); BDE-85 (A), BDE-153 (B), and BDE-154 (C) in human placenta from 1998 through 2006. The scatter plots 
illustrate the samples with detectable congeners. Numbers below the x-axis are the percentages of samples per year that had detectable levels. The dashed line 
represents the trend over the 9-year period using all of the samples per year (i.e., including zeros), and the solid line shows the trend using only placenta with 
detectable levels of each BDE congener. Statistical analyses of trends were done using data from all samples.
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beginning in the early 1990s has resulted in 
static or decreasing PBDE levels in European 
nonpregnant, maternal, and cord sera and in 
breast milk samples (Darnerud et al. 2002; Law 
et al. 2006, 2008), the manufacture and sale 
of these PBDE mixtures was halted in North 
America (by consent of the manufacturer) on   
1 January 2004.
Since the 1990s, studies of environmental 
and human specimens in North America have 
uniformly documented a dramatic increase 
in PBDE levels (de Wit et al. 2006; Li et al. 
2006; Pereg et al. 2003; Ryan et al. 2002; 
Schecter et al. 2004; Solomon and Weiss 
2002). What is worrisome, based on our find-
ings and those of others, is that these high lev-
els appear to be passing freely from the mother 
to the fetus from very early in gestation, as well 
as postnatally through breast-feeding (Mazdai 
et al. 2003; Ryan and van Oostdam 2004; 
Schecter et al. 2007). For the past 20–30 years, 
PBDEs have been used as additives in many 
plastics, foams, and other long-lived prod-
ucts that have widespread use commercially 
as well as in the home. Despite the present 
lack of penta- and octa-BDE manufacturing 
in North America, these PBDEs will continue 
to be slowly released into the environment, 
concurrently contaminating the food chain, 
in the coming years. Personal lifestyle choices 
(e.g., food options), age, occupation, meta-
bolism, and tissue burden before 2004 will 
all affect blood, breast milk, and tissue con- 
taminant levels (Allen et al. 2007; Birnbaum 
and Hubal 2006; Birnbaum and Staskal 2004; 
Lorber 2008; McDonald 2002). It is encour-
aging, however, that although initial studies 
by Ryan et al. (2002) found that median levels 
of PBDEs in human milk samples collected 
across Canada had increased an order of mag-
nitude from 1992 through 2002 (from 2.9 to 
25.0 ng/g lipid), a more recent study analyzing 
breast milk samples from Hamilton, Ontario, 
found that the levels in 2005 samples were 
slightly, but not statistically, lower than the 
samples collected in Hamilton previously, sug-
gesting that the amount of PBDEs in breast 
milk samples from that region of Canada may 
be starting to plateau (Ryan et al. 2006).
On average, the concentrations of PBDEs 
as well as OCs and PCBs in our liver sam-
ples were appreciably higher than those in 
the placenta, suggesting tissue-specific bio-
accumulation. This may be due in part to the 
relative difference in their lipid content (our 
average for liver was 2.56%, versus 1.31% 
for placenta). However, the lack of a correla-
tion within the paired samples in our study, 
as well as the results from investigations of 
paired maternal and cord sera (Antignac et al. 
2008; Guvenius et al. 2003; Hirai et al. 2004; 
Mazdai et al. 2003), suggest that these lipo-
philic contaminants are passing relatively freely 
through the placental tissue and into the fetal 
circulation, regardless of their level of bromi-
nation, and then are likely accumulating in the 
liver over time. This concept is supported by 
the fact that the percentages of the seven BDE 
congeners we measured in both the placental 
and liver tissues closely resemble those found 
in the commercial DE-71 mixture. Thus, the 
placenta does not appear to provide much of a 
barrier for these contaminants at early to mid-
gestation (present data) or at term (Antignac 
et al. 2008; Guvenius et al. 2003; Hirai et al. 
2004; Mazdai et al. 2003).
Although 84% of our PBDE values were 
in the range of 0–1,500 ng/g lipid, two liver 
and three placental samples had levels approxi-
mately 10- to 100-fold higher. Unfortunately, 
these were not among the paired samples, but 
that may not have provided much insight into 
whether the mother’s BDE burden greatly 
exceeded the population’s average because we 
found no association between the amount of 
PBDEs in our fetal liver and placental samples. 
We analyzed samples collected anonymously, 
therefore neither our present study nor that 
of Schecter et al. (2007) has any information 
about maternal PBDE exposure that could 
help to explain the high levels.
Interestingly, ours is not the only report 
of PBDE concentrations that vary markedly 
among samples. In a review of Canadian breast 
milk studies, Gill et al. (2004) noted that PBDE 
concentrations differed by three orders of mag-
nitude, a variability that they did not see with 
PCBs and dioxins. Both Gill et al. (2004) and 
Birnbaum and Hubal (2006) also observed that 
PBDE biomonitoring studies from several coun-
tries found “outliers” in diverse human speci-
mens. More recently, researchers at the U.S. 
Centers for Disease Control and Prevention 
have determined PBDE concentrations in the 
blood of > 2,000 Americans: the highest levels 
were in the youngest group (12–19 year olds) 
(Sjodin et al. 2008). They also reported that the 
highest concentration in one subject’s blood 
(3,680 ng/g lipid) was more than 12 times the 
average value for the 95th percentile (291 ng/g 
lipid) and that 5% of their population had 
PBDE levels more than seven times the geo-
metric mean. Although an explanation for such 
fluctuations was not readily apparent, factors 
such as proximity to the source of contamina-
tion, length of exposure, exposure to different 
PBDE commercial mixtures, and differences in 
individual nutritional status, absorption, metab-
olism, and excretion are likely contributing fac-
tors (Athanasiadou et al. 2008; Stapleton et al. 
2008; Van den Steen et al. 2008; Zhao et al. 
2008). Interestingly, the major source of PBDE 
exposure for most humans appears to be the 
dust associated with household and commercial 
consumer products (Athanasiadou et al. 2008; 
Lorber 2008).
Figure 5. Comparison of the percentage distribution for total PBDE congeners (47, 85, 99, 100, 153, 154, and 183), 
total PCB congeners (49, 99, 118, 137, 138, 153, and 180), and total OCs (DDT, DDE, trans-nonachlor, HCB) in 
human fetal liver and placenta obtained from elective terminations of 11.25- to 20-week fetuses in the Greater 
Montreal area of Quebec during 1998 [(A) liver, n = 6; (C) placenta, n = 4; 13.8- to 20-week fetal age] and during 
2006 [(B) liver, n = 4; (D) placenta, n = 7; 11.25- to 16.5-week fetal age], for all the samples analyzed.
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In summary, our study of POPs in human 
fetal liver and placental tissues suggests that 
PBDEs, PCBs, and OCs are passing into and 
accumulating within the fetal compartment 
from a very early stage in gestation. Although 
we found little change in the relative amounts 
of the PCBs and OCs from 1998 through 
2006, there has been a significant increase in 
the fetal liver levels of PBDEs. These data, 
along with the results from previous studies 
of human postnatal blood, breast milk, and 
adipose tissues, suggest increased exposure of 
humans to PBDEs at every stage in life during 
the past decade. Although this appears to be 
more of an issue in North America, the wide-
spread presence of PBDEs in commercial and 
household items as well as in the environment 
and food chain ensures that this is a universal 
problem. Whether some individuals are reach-
ing an exposure level that may constitute a 
danger to their health is unknown. Annual 
monitoring programs (e.g., blood, breast milk, 
fetal tissues, meconium, hair) in different 
regions would help to answer how the body 
burdens are changing in the future and pro-
vide important dose information for studies of 
the physiologic effects of these contaminants.
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